Of course the mar­ket de­ba­cle will in­flu­ence M&A, deal­mak­ing. The pen­du­lum is swing­ing back to buy­ers

Do you think cer­tain M&A tar­gets look more in­ter­est­ing to you giv­en the sig­nif­i­cant pull­back in biotech val­u­a­tions? Or do you still think some of these good as­sets are over­val­ued? And do you think com­pa­nies and boards of mid-cap biotechs have ca­pit­u­lat­ed to val­u­a­tion re­sets, or will that take more time?

Louise Chen at Can­tor Fitzger­ald didn’t waste any time in get­ting to one of the big bio­phar­ma ques­tions of 2022: Are we about to see a surge of M&A and deals now? And how does the bear mar­ket in biotech stocks in­flu­ence that?

Endpoints Premium

This article is for premium subscribers only

Upgrade to a premium subscription plan for unlimited access, and join our community of key biopharma players.